

Investors Newsletter

Number 2

June 1, 2014



We have arrived to the launching Pad. E-QUIRE is ready to start executing its Business plan which is pursuing FDA approval for the E-QUIRE BST medical device.

We are completing the transfer of the patents to the public company, and registering it on its name. Lifewave has notified us that the deal with them is complete and all conditions for executing it were achieved.

ADBI (the public company) has filed for re-domiciling into Delaware. Effective is expected soon. It is also finalizing the 1/100 reverse split to form the promised 15M new Delaware shares prior to the private placement closing.

The public company finalized the Clean-up, and it is now clear of any obligations to third parties.

The Private Placement looks like a success. We required a minimum of \$2M, We wanted to raise \$2.4M, and we are supposed to finish this round with \$2.6M. PP Subscriptions agreements are on the Email to the investors.

We have finalized the agreement with the US CRO, who is going to conduct the FDA regulatory process for us. Signing is expected this week and work has already been commenced.

The Public company is notifying the nomination of Mr. Ohad Goren as CEO, and Mr. Itzik Ben Yesha as CTO of the company. Both individuals are well acquainted with our product and their Resume is in the presentation and the Web Site.

The company has completed its initial Web Site at www.e-quire.com. We also have a company page on LinkedIn. Please look for us and share with your connections. You can also follow us on Tweeter.

To all our investors:
from the next newsletter, and once we have completed the private placement and start operating under the public company umbrella, the newsletters will be issued as formal press releases to all our shareholders.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. We are using forward-looking statements, when we discuss items in this document. These forward-looking statements and their implications are based on the current expectations of the management of E-QUIRE only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of E-QUIRE to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, E-QUIRE undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting E-QUIRE, reference is made to E-QUIRE's reports filed from time to time with the Securities and Exchange Commission.